Radiation Oncology Department, Capio-Hospital General de Catalunya, Sant Cugat del Vallés, Barcelona, Spain.
Clin Transl Oncol. 2010 Jan;12(1):43-8. doi: 10.1007/s12094-010-0465-0.
Radio-induced dermatitis is one of the most frequent side effects of radiotherapy. Among the commercially available products for the care of irradiated skin is a hydrating lotion containing 3% urea, polidocanol and hyaluronic acid. Its effectiveness for preventing the appearance of radiodermatitis or reducing its severity has been studied on a number of occasions.
To evaluate the effectiveness of "intensive use" of the lotion containing 3% urea, polidocanol and hyaluronic acid for preventing the appearance of acute radiodermatitis and controlling its severity.
Prospective observational study in 98 patients with breast cancer with a 10-week follow-up period. Skin toxicity (RTOG/EORTC scale) was evaluated weekly. To study the effectiveness we compared incidence and grade of toxicity with a sample of 174 breast cancer patients (control sample) treated in our centre during 2006 who used skin-support measures at the start of the radiotherapy or the occurrence of radiodermatitis.
The proportion of patients who did not develop radiodermatitis was significantly higher in the intensive use group (27.6% vs. 15.5%; p<0.05; OR: 2.07). Compared with the same lotion in standard conditions, the intensive use group showed lower incidence of radiodermatitis (p<0.01), lower grade of toxicity (p<0.001) and lower proportion of radiodermatitis grade 2 or higher (p<0.01).
Intensive use of the lotion doubles the likelihood that breast cancer patients will not develop radiodermatitis during radiotherapy. Furthermore, compared with standard use, intensive use is more effective in reducing the incidence of skin toxicity and skin toxicity grade 2 or higher.
放射性皮炎是放疗最常见的副作用之一。市售的用于治疗放射性皮肤损伤的产品中,有一种含有 3%尿素、聚多卡醇和透明质酸的保湿乳液。已经有许多研究评估了其预防放射性皮炎发生或减轻其严重程度的效果。
评估“密集使用”含有 3%尿素、聚多卡醇和透明质酸的乳液预防急性放射性皮炎发生和控制其严重程度的效果。
对 98 例乳腺癌患者进行前瞻性观察研究,随访 10 周。每周评估皮肤毒性(RTOG/EORTC 量表)。为了研究其有效性,我们将本研究中 98 例患者的毒性发生率和严重程度与在我们中心治疗的 174 例乳腺癌患者(对照组)进行了比较,对照组在放疗开始时使用皮肤支持措施或发生放射性皮炎。
密集使用组未发生放射性皮炎的患者比例明显高于标准使用组(27.6% vs. 15.5%;p<0.05;OR:2.07)。与标准条件下的同一种乳液相比,密集使用组放射性皮炎的发生率较低(p<0.01),毒性严重程度较低(p<0.001),2 级或以上放射性皮炎的比例较低(p<0.01)。
密集使用该乳液可使乳腺癌患者放疗期间发生放射性皮炎的可能性降低一半。此外,与标准使用相比,密集使用在降低皮肤毒性和 2 级或以上皮肤毒性的发生率方面更有效。